Oslo, United States
ClexBio, founded in 2021, is emerging as a pioneer in the biotechnology and health care sectors. The company, based in the United States, is making significant strides in regenerative medicine with its groundbreaking platform for scalable and high-throughput generation of therapeutic tissues.
The driving philosophy behind ClexBio is embodied in their slogan, "Technology should enable biology, not replace it." They are at the forefront of advancing the next generation of cell therapy by utilizing fully functional bioengineered tissues. This innovation is set to deliver a new class of curative treatments for some of the most challenging medical conditions worldwide.
The company attracted attention from investors like Iaso Ventures, which participated in an undisclosed last investment round dated 01 January 2023. ClexBio represents a promising investment opportunity for those interested in transformative healthcare technologies that harness biology's potential.
